Results 31 to 40 of about 17,802 (177)

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
Nabil K. El Ayoubi, Sola Al Ghazal, Salem Hannoun, Medhat A. Siddik, Nour M. Najjar, Jim Dagher, Joseph Abboud, Myriam G. Semaan, Samia J. Khoury   +8 more
wiley   +1 more source

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series

BMC Neurology, 2021
Background Fingolimod is a S1P1 receptor modulator that prevents activated lymphocyte egress from lymphoid tissues causing lymphopenia, mainly affecting CD4+ T lymphocytes.
Silvia Delgado, Jeffrey Hernandez, Leticia Tornes, Kottil Rammohan   +3 more
doaj   +1 more source

Baseline Neuroinflammation Stratifies TSPO‐PET Response to Disease‐Modifying Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch, Markus Matilainen, Giulia N. Baldrighi, Marjo Nylund, Maija Saraste, Laura Airas   +5 more
wiley   +1 more source

Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis [PDF]

, 2018
BACKGROUND AND PURPOSE: In 2011, fingolimod was approved in Switzerland for the treatment of relapsing-remitting multiple sclerosis (RRMS). The aim of the present study was to assess the effectiveness and retention of fingolimod in a real-life Swiss ...
C. P. Kamm, A. Baumann, O. Findling, C. Zecca, Findling, O., Kamm, Christian Philipp, Baumann, A., Lalive, P. H., Czaplinski, A., Roth, S., A. Czaplinski, Perriard, G., Bachmann, V., S. Roth, Pless, M. L., G. Perriard, P. H. Lalive, V. Bachmann, Zecca, C., M. L. Pless   +19 more
core   +2 more sources

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto, Dariia Kliushnikova, Richard Friedrich Radlberger, Sinan Yasaroglu, Tobias Moser, Andrea Harrer, Kitty Kratzer, Wolfgang Hitzl, Christiane Gradl, Martin Schmidauer, Patrick Roth, Harald Hegen, Peter Wipfler   +12 more
wiley   +1 more source

Intracerebral Hemorrhage Induces Monocyte TNF Signaling in Patients That Is Suppressed by BAF312

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Intracerebral hemorrhage (ICH) causes high morbidity and mortality, with neurotoxic inflammation driven by infiltrating monocytes. This study is an in‐depth longitudinal examination of the immune response during the first week of ICH in the presence and absence of the immunomodulatory drug BAF312 (Siponimod).
Jonathan Howard DeLong, Sebastian Díaz‐Pérez, Kevin Navin Sheth, Jang‐Ho Cha, C. J. Malanga, Patricia G. M. Wagner, Nicole Pezous, Aurelie Hanin, Kyle B. Walsh, H. E. Hinson, Lauren Hachmann Sansing   +10 more
wiley   +1 more source

A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome [PDF]

, 2014
r.
Kelly Pegoretti Baruteau, Gnanasambandam, Sakthivel, Schmierer, Klaus, Zane Jaunmuktane, Gnanapavan, Sharmilee, Gnanapavan, S, Klaus Schmierer, Sharmilee Gnanapavan, Gnanasambandam, S, Schmierer, K, Baruteau, KP, Jaunmuktane, Z, Jaunmuktane, Zane, Pegoretti Baruteau, Kelly, Sakthivel Gnanasambandam   +14 more
core   +2 more sources

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis

Journal of Investigative Medicine High Impact Case Reports, 2015
A man with relapsing multiple sclerosis, treated with fingolimod 0.5 mg/d for 15 months, developed acute lymphoblastic leukemia and died 4 months after immune ablation and bone marrow allograft, from graft versus host disease.
Stanley Cohan MD, PhD, John Godwin MD, Leah Gaedeke FNP   +2 more
doaj   +1 more source

Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis

Journal of Ophthalmic Inflammation and Infection, 2020
Background Patients with multiple sclerosis (MS) have a higher incidence of uveitis compared with the general population. Fingolimod, a first line disease modifying drug used in multiple sclerosis, may cause macular edema and thus requires ophthalmic ...
Scott Joseph Sonne, Bradley Thomas Smith
doaj   +1 more source

Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing. [PDF]

PLoS ONE, 2015
In multiple sclerosis (MS) patients, Fingolimod may induce prolonged heart-rate slowing which might be caused by MS-related central autonomic lesions.To evaluate whether MS-patients with prolonged heart-rate slowing (> six hours) upon Fingolimod show ...
Max J Hilz, Tassanai Intravooth, Sebastian Moeller, Ruihao Wang, De-Hyung Lee, Julia Koehn, Ralf A Linker   +6 more
doaj   +1 more source